Image Source: UnsplashDeals and Financings
Japan’s Takeda acquired global rights to an Alzheimer’s therapy developed by AC Immune SA of Switzerland for $100 million upfront and up to $2.1 billion in milestones;
San Diego’s Erasca in-licensed two China-developed pre-clinical RAS candidates in two separate agreements with a total value of $359 million;
Shenzhen Beimei Pharma acquired greater China rights for Twyneo®, a therapy for acne vulgaris, from Israel’s Sol-Gel (SLGL) for $15 million;
Trials and Approvals
Shanghai’s Zai Lab reported China’s NMPA approved repotrectinib for adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer;
Shanghai Everest Medicines launched Nefecon®, a treatment for IgA nephropathy in China, a glomerular disease that can cause end-stage renal disease;
Suzhou Ractigen Therapeutics announced approval of its China IND for RAG-17 as a therapy for Amyotrophic Lateral Sclerosis;
Beijing InnoCare Pharma completed enrollment in a China Phase II trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor for psoriasis therapy;
Shanghai Mabwell reported positive data from a China trial of its novel Nectin-4-targeting ADC for triple-negative breast cancer;
Nanjing IASO Bio announced a single-cell analysis was published in a scientific journal for its anti-BCMA CAR T cell therapy that targets neuromyelitis optica spectrum disorder.
More By This Author:Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal